Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P47895

UPID:
AL1A3_HUMAN

ALTERNATIVE NAMES:
Aldehyde dehydrogenase 6; Aldehyde dehydrogenase family 1 member A3

ALTERNATIVE UPACC:
P47895; Q6NT64

BACKGROUND:
Retinaldehyde dehydrogenase 3, identified by its high specificity for all-trans-retinal, catalyzes essential reactions for the production of retinoate, a critical lipid in eye and nasal development. It is known alternatively as Aldehyde dehydrogenase 6 and Aldehyde dehydrogenase family 1 member A3.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Microphthalmia, isolated, 8, Retinaldehyde dehydrogenase 3's function in eye formation disorders underscores its potential as a target for therapeutic intervention. Understanding its role could lead to breakthroughs in treating developmental eye diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.